330 related articles for article (PubMed ID: 31954534)
1. Evolving population-based statistics for rare epithelial ovarian cancers.
Matsuo K; Machida H; Matsuzaki S; Grubbs BH; Klar M; Roman LD; Sood AK; Gershenson DM; Wright JD
Gynecol Oncol; 2020 Apr; 157(1):3-11. PubMed ID: 31954534
[TBL] [Abstract][Full Text] [Related]
2. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
Kucukgoz Gulec U; Paydas S; Guzel AB; Vardar MA; Khatib G; Gumurdulu D
Arch Gynecol Obstet; 2015 Oct; 292(4):923-9. PubMed ID: 25855053
[TBL] [Abstract][Full Text] [Related]
3. Comparison of stage III mucinous and serous ovarian cancer: a case-control study.
Firat Cuylan Z; Karabuk E; Oz M; Turan AT; Meydanli MM; Taskin S; Sari ME; Sahin H; Ulukent SC; Akbayir O; Gungorduk K; Gungor T; Kose MF; Ayhan A
J Ovarian Res; 2018 Oct; 11(1):91. PubMed ID: 30376858
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
Matsuo K; Machida H; Grubbs BH; Matsuzaki S; Klar M; Roman LD; Sood AK; Gershenson DM
Gynecol Oncol; 2020 Apr; 157(1):21-28. PubMed ID: 31954535
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
Oseledchyk A; Leitao MM; Konner J; O'Cearbhaill RE; Zamarin D; Sonoda Y; Gardner GJ; Long Roche K; Aghajanian CA; Grisham RN; Brown CL; Snyder A; Chi DS; Soslow RA; Abu-Rustum NR; Zivanovic O
Ann Oncol; 2017 Dec; 28(12):2985-2993. PubMed ID: 28950307
[TBL] [Abstract][Full Text] [Related]
6. Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.
Matsuo K; Matsuzaki S; Maeda M; Rau AR; Yoshihara K; Tamura R; Shimada M; Machida H; Mikami M; Klar M; Roman LD; Wright JD; Sood AK; Gershenson DM
JAMA Netw Open; 2023 Jun; 6(6):e2318602. PubMed ID: 37326992
[TBL] [Abstract][Full Text] [Related]
7. Prognosis comparison between small cell carcinoma of ovary and high-grade serous ovarian cancer: A retrospective observational cohort study.
Hu D; Ma D; Zhang ZJ; Zhang Y; Huang K; Li X
Front Endocrinol (Lausanne); 2023; 14():1103429. PubMed ID: 36742399
[TBL] [Abstract][Full Text] [Related]
8. Histological Tumor Type is Associated with One-Year Cause-Specific Survival in Women with Stage III-IV Epithelial Ovarian Cancer: A Surveillance, Epidemiology, and End Results (SEER) Database Population Study, 2004-2014.
Wu SG; Li FY; Lei J; Hua L; He ZY; Zhou J
Med Sci Monit; 2020 Feb; 26():e920531. PubMed ID: 32008036
[TBL] [Abstract][Full Text] [Related]
9. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas.
Dong S; Yu F; Liu Y; Yu X; Sun X; Wang W; Wang Y
Ginekol Pol; 2023; 94(10):792-798. PubMed ID: 36477777
[TBL] [Abstract][Full Text] [Related]
11. Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study.
Machida H; Matsuo K; Yamagami W; Ebina Y; Kobayashi Y; Tabata T; Kanauchi M; Nagase S; Enomoto T; Mikami M
Gynecol Oncol; 2019 Jun; 153(3):589-596. PubMed ID: 30905436
[TBL] [Abstract][Full Text] [Related]
12. Differences between complex epithelial neoplasms of the ovary and high-grade serous ovarian cancer: a retrospective observational cohort study.
Li X; Ding Y; Liu Y; Yang M
J Ovarian Res; 2022 Dec; 15(1):125. PubMed ID: 36456989
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
Matsuo K; Hasegawa K; Yoshino K; Murakami R; Hisamatsu T; Stone RL; Previs RA; Hansen JM; Ikeda Y; Miyara A; Hiramatsu K; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Roman LD; Gabra H; Fotopoulou C; Sood AK
Eur J Cancer; 2015 Sep; 51(14):1978-88. PubMed ID: 26238017
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Survival Among Histological Subtypes in Advanced Epithelial Ovarian Cancer: Population-Based Study Using the Surveillance, Epidemiology, and End Results Database.
Yang SP; Su HL; Chen XB; Hua L; Chen JX; Hu M; Lei J; Wu SG; Zhou J
JMIR Public Health Surveill; 2021 Nov; 7(11):e25976. PubMed ID: 34787583
[TBL] [Abstract][Full Text] [Related]
15. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
Sahin H; Sari ME; Cuylan ZF; Haberal AN; Sirvan L; Coban G; Yalcin I; Güngör T; Celik H; Meydanli MM; Ayhan A
Arch Gynecol Obstet; 2018 Apr; 297(4):1005-1013. PubMed ID: 29383437
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.
Martins FC; Couturier DL; Paterson A; Karnezis AN; Chow C; Nazeran TM; Odunsi A; Gentry-Maharaj A; Vrvilo A; Hein A; Talhouk A; Osorio A; Hartkopf AD; Brooks-Wilson A; DeFazio A; Fischer A; Hartmann A; Hernandez BY; McCauley BM; Karpinskyj C; de Sousa CB; Høgdall C; Tiezzi DG; Herpel E; Taran FA; Modugno F; Keeney G; Nelson G; Steed H; Song H; Luk H; Benitez J; Alsop J; Koziak JM; Lester J; Rothstein JH; de Andrade JM; Lundvall L; Paz-Ares L; Robles-Díaz L; Wilkens LR; Garcia MJ; Intermaggio MP; Alcaraz ML; Brett MA; Beckmann MW; Jimenez-Linan M; Anglesio M; Carney ME; Schneider M; Traficante N; Pejovic N; Singh N; Le N; Sinn P; Ghatage P; Erber R; Edwards R; Vierkant R; Ness RB; Leung S; Orsulic S; Brucker SY; Kaufmann SH; Fereday S; Gayther S; Winham SJ; Kommoss S; Pejovic T; Longacre TA; McGuire V; Rhenius V; Sieh W; Shvetsov YB; Whittemore AS; Staebler A; Karlan BY; Rodriguez-Antona C; Bowtell DD; Goode EL; Høgdall E; Candido Dos Reis FJ; Gronwald J; Chang-Claude J; Moysich KB; Kelemen LE; Cook LS; Goodman MT; Fasching PA; Crawford R; Deen S; Menon U; Huntsman DG; Köbel M; Ramus SJ; Pharoah PDP; Brenton JD
Br J Cancer; 2020 Sep; 123(5):793-802. PubMed ID: 32555365
[TBL] [Abstract][Full Text] [Related]
17. Low-grade serous ovarian carcinoma: A comprehensive literature review.
Goulding EA; Simcock B; McLachlan J; van der Griend R; Sykes P
Aust N Z J Obstet Gynaecol; 2020 Feb; 60(1):27-33. PubMed ID: 31849044
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer.
Cohen JG; Prendergast E; Geddings JE; Walts AE; Agadjanian H; Hisada Y; Karlan BY; Mackman N; Walsh CS
Gynecol Oncol; 2017 Jul; 146(1):146-152. PubMed ID: 28501328
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma.
Voutsadakis IA
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():172-178. PubMed ID: 33246201
[TBL] [Abstract][Full Text] [Related]
20. The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction.
Johnson RL; Laios A; Jackson D; Nugent D; Orsi NM; Theophilou G; Thangavelu A; de Jong D
J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
